UNASSIGNED: e15018 Background: This study sought to evaluate @entity5 -specific outcomes among @entity1 who received perioperative @entity1138 ( @entity1139 ) prior to induction BCG versus those who received induction BCG alone. METHODS: Between January 2000 and August 2010, 260 @entity1 were identified who underwent a course of induction BCG with or without concomitant perioperative @entity1139 . Specifically, @entity1 who received 40 mg @entity1139 following transurethral resection of all visible @entity5 followed by an induction course of BCG were compared to a similar cohort of @entity1 who received induction BCG alone. The primary endpoints were overall and @entity1349 ( @entity1349 ). RESULTS: A total of 212 @entity1 were identified who received induction BCG alone, and 48 who received perioperative @entity1139 with induction BCG. The aggregate @entity1 cohort was comprised of those with non-muscle-invasive disease (NMI), and there was no difference between groupings with respect to common demographic and pathologic variables. Over a median follow-up of 34.5 months, there was no difference in overall survival between cohorts. @entity1349 was superior among @entity1 who received combined therapy (5 year survival: 37.5% vs 56.3%, p=0.023). Nevertheless, the regimen of intravesical therapy did not reach significance as an independent predictor (HR 0.61, p= 0.055, CI 0.36-1.01). CONCLUSIONS: Although the combination therapy group demonstrated a significant @entity1349 advantage, the intravesical therapy regimen did not independently modulate this benefit. Further investigation is warranted to determine if immediate @entity1139 prior to a course of induction BCG confers a benefit to @entity1349 .

Maximizing intravesical therapy options: Is there an advantage to the administration of perioperative XXXX prior to an induction course of BCG?

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin C'] @entity1139 :: ('CHEBI:27504', 'Chemical') :: ['MMC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['RFS', 'recurrence-free survival']
@entity1138 :: (MESH:D016685,Chemical) :: ['mitomycin C']
